HOOKIPA Pharma Inc.
2.60%
314,259
1760542
43906K209
Feb 13, 2025
Feb 14, 2025, 04:25 PM
Reporting Persons (8)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Sofinnova Capital VI FCPR | Other | 2.60% | 314,259 | 314,259 | 0 |
| Sofinnova Partners SAS | Other | 2.60% | 314,259 | 314,259 | 0 |
| Antoine Papiernik | Individual | 2.60% | 314,259 | 314,259 | 0 |
| Henrijette Richter | Individual | 2.60% | 314,259 | 314,259 | 0 |
| Maina Bhaman | Individual | 2.60% | 314,259 | 314,259 | 0 |
| Graziano Seghezzi | Individual | 2.60% | 314,259 | 314,259 | 0 |
| Anta Gkelou | Individual | 2.60% | 314,259 | 314,259 | 0 |
| Karl Naegler | Individual | 2.60% | 314,259 | 314,259 | 0 |
Disclosure Items (3)
Common Stock, par value $0.0001 per share
HOOKIPA Pharma Inc.
350 Fifth Avenue, New York, NY, 10118
Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: This Amendment is being filed to reflect a decrease in the Reporting Persons' percentage ownership of the Issuer's Common Stock, which resulted from an increase in the number of shares outstanding since the filing of Amendment No. 4 to Schedule 13D and is not due to any transactions in the shares of Common Stock by the Reporting Persons. Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.
Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: See the information contained on the cover pages of this Amendment, which is incorporated herein by reference.
Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: There have been no reportable transactions with respect to the shares of Common Stock of the Issuer within the last 60 days by the Reporting Persons.
The amount of outstanding shares of Common Stock was substantially increased in June 2023 when the Issuer closed a public offering of Common Stock.
EX 99.1 - Joint Filing Agreement, dated as of February 14, 2025, by and among Sofinnova Capital VI FCPR, Sofinnova Partners SAS, Antoine Papiernik, Henrijette Richter, Maina Bhaman, Graziano Seghezzi, Anta Gkelou and Karl Naegler